Nobis Nobis Cartel windows 7 home premium activation key 70-290

Bullous pemphigoid and pemphigus vulgaris rates climbing in U.K.

If you look at these kinds of data sets across almost all diseases, the incidence seems to increase over time. It’s probably an issue of chronic diseases being picked up over time.


KYOTO, JAPANThe annual incidence of both bullous pemphigoid and pemphigus vulgaris has climbed steadily over the past decade in the United Kingdom for reasons unknown, according to a study of more than 1,000 patients.

The mortality associated with these autoimmune diseases may have beenunderestimated in the past, based upon the results of Dr. Sinead Langan’s large, population-based study presented at an international investigative dermatology meeting.People with bullous pemphigoid are twice as likely to die and those with pemphigus vulgaris are three times as likely to die as [are] matched controls,” said Dr. Langan of the University of Nottingham (England).


[ILLUSTRATION OMITTED]
Her study of The Health Improvement Network (THIN)–a large, population-based database of computerized primary care medical recordsidentified 868 patients diagnosed with bullous pemphigoid (BP) and 139 diagnosed with pemphigus vulgaris (PV) during 1996-2006. Each patient was matched by age and gender with four controls from the same general practice.She undertook the study because, despite the substantial morbidity and mortality associated with these autoimmune diseases, little is known about their epidemiology. For example, there are only two published studies addressing PV mortality; one, from the Middle East, reported a 1-year mortality of 5%, while a 1975 U.S. study found a 50% 1-year mortality, she said. The reported BP mortality has cut a similarly wide swath.

The incidence of BP in the new U.K. study climbed with advancing age, peaking in a group aged 80-84 years. The median age at presentation was 80 years, and 62% of affected patients were women.

PV incidence showed a bimodal distribution, with a peak at ages 45-49 years and a second, larger one at 80-84 years. Median age at presentation was 71 years, and two-thirds of patients were women.

The incidence of BP was 4.3 cases/100,000 person-years; for PV it was 0.7/100,000 person-years. The incidence of BP showed adramaticaverage yearly increase of 17% during the study period, while PV incidence increased by 11% each year, according to Dr. Langan. The 1-year mortality rate among patients with BP was 19%, resulting in an estimated 70 excess deaths/1,000 person-years. After adjustment for age and gender as potential confounders, BP patients had a 2.3-fold greater risk of mortality than did controls. The adjusted mortality risk in PV patients was 3.4-fold greater than in controls; PV resulted in 62 excess deaths / 100,000 person-years.

Dr. Joel M. Gelfand commented that he doesn’t believe the rising annual incidence rates of BP and PV observed in the U.K. study are real, and suspects that more sophisticated statistical analyses would show as much.

If you look at these kinds of data sets across almost all diseases, the incidence seems to increase over time. It’s probably an issue of chronic diseases being picked up over time,” according to Dr. Gelfand, who has led several landmark studies carefully documenting increased cardiovascular and cerebrovascular risks in psoriasis patients using the U.K. General Practice Research Database. He is medical director of the clinical studies unit in the department of dermatology at the University of Pennsylvania, Philadelphia.

Dr. John R. Stanley, professor and chair of dermatology at the University of Pennsylvania, said Dr. Langan’s study left him uncertain about how to apply the findings in clinical practice. “We don’t know [from the U.K. study] whether to treat more aggressively or less,” Dr. Stanley observed at a meeting of the European Society for Dermatological Research, the Japanese Society for Investigative Dermatology, and the Society for Investigative Dermatology.

Dr. Langan agreed these data are not illuminating on that score. However, the database also contains information on medications, and she is planning a study she hopes will help guide treatment decisions.

BY BRUCE JANCIN


Related Articles


Peptimmune begins Phase I trial for pemphigus vulgaris.
Peptimmune has announced that it has initiated a Phase I clinical trial to test the safety of PI-0824 in patients with pemphigus vulgaris (PV). The study is being undertaken at four sites. PI-0824 is a synthetic injectible peptide being developed ……


A 27-year-old man presented with a 2-day history of pruritic blisters scattered on the trunk and proximal extremities. Against an erythematous, edematous background, tense bullae up to 8 cm in diameter were also present on the face. Two weeks after ……

CASE OF THE MONTH.
BANFF, ALTA. — Pemphigus vulgaris is rare in childhood, Dr. Jeffrey Callen said in a poster session at the annual meeting of the Society for Pediatric Dermatology. The disease usually occurs between 40 and 60 years of age. Dermatologically, oral ……

Cosmeceutical critique: niacinamide.
Unlike many cosmeceutical ingredients, there is a great deal of research that supports the use of topical niacinamide. Studies have shown its usefulness in increasing synthesis of collagen and lipids, inhibiting the transfer of melanosomes, and decreasing inflammation. As a ……


Randomized controlled study to evaluate CellCept in the treatment of pemphigus vulgaris.
Aspreva Pharmaceuticals Corporation is currently working to provide more evidence-based medicines for less common diseases. The company recently announced the initiation of a Phase III trial to evaluate the safety and efficacy of CellCept (mycophenolate mofetil) with corticosteroids to achieve ……


HLA typing identifies pemphigus risk factors.
ZURICHThe human leukocyte antigen class II DRB1*0402 allele proved to be the strongest genetic risk factor for pemphigus vulgaris in both whites and IndoAsians in the largest HLA typing study to date conducted in a European population, Dr….


Pemphigus vulgaris.
A recent study published in the Archives of Dermatology evaluated adjuvant therapy with oral dexamethasone pulse therapy in the treatment of pemphigus vulgaris. (2) This randomized, multi-center, placebo-controlled trial evaluated 20 patients with new pemphigus vulgaris. Patients were randomized to ……

Abstract Pemphigus Foliaceus (PF) is an antibody-mediated autoimmune disease. IgG directed against desmoglein-1 induces acantholysis in the superficial epidermis, leading to the classic presentation of crusted erosions in a seborrheic distribution. We report a case of a 51-year-old African-American man ……

Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists.
The authors in this study injected littermates of neonatal athymic nude mice with pemphigus vulgaris (PV) to determine whether a cholinergic agonist can abolish PV IgG-induced acantholysis. Previous studies have determined the importance of cholinergic receptors in the pathogenesis of ……

Know Cutaneous Signs of Internal Malignancies.
SEA ISLAND, GA. — Manyofthe7%15% of patients with internal malignancy who develop cutaneous paraneoplasias will seek care for these dermatologic conditions first, so family physicians should be alert to their significance for early diagnosis, Dr. Toni L. McCullough said at ……


Autoantibodies for bullous pemphigoid found in unaffected.
KYOTO, JAPANMore than 7% of individuals without any form of autoimmune disease possess elevated serum bullous pemphigoid 180 and/or BP230 autoantibodies on the commercially available enzyme-linked immunosorbent assay, according to testing of stored serum from 370 people. These ……


Youth, mucosal disease predict pemphigus relapse.
SORRENTO, ITALYPatients with pemphigus who are younger than 40 years at the time of diagnosis and whose first remission is brief are likely to have a more severe course of disease and multiple relapses, Dr. David Mimouni said ……


IVIg for refractory pemphigus. (Steroid-Resistant Disease).
NEW ORLEANSIntravenous immunoglobulin helped to get pemphigus under control in patients with disease refractory to systemic steroids. In two studies, 15 patients with moderate to severe pemphigus vulgaris and 7 patients with severe pemphigus foliaceus experienced significant improvement ……


Erythema gyratum repens in a case of resolving psoriasis.
Abstract Erythema gyratum repens (EGR) is a rare skin syndrome often associated with internal malignancies, and thus considered paraneoplastic (1). There are cases of erythema gyratum repens in the literature associated with other dermatoses without underlying malignancies’. We present a ……


A practical technique for differentiation of sub-epidermal bullous diseases: localization of in vivo-bound IGG by laser scanning confocal microscopy.

The purpose of this study was to develop a practical technique to distinguish autoimmune sub-epidermal bullous diseases.The authors present a prospective study from an academic referral center. The patient population consisted of forty-two patients fulfilling clinical, immunological, and/or immunoelectron microscopic ……


נשלח ב Multimedia

JOIN TODAY!

The P/P Registry has been approved by the Western Institutional Review Board (WIRB) and is actively enrolling participants.

ENGLISH VERSION